CA Patent

CA3219397A1 — Tetracyclic compounds for the treatment of zika virus infection

Assigned to Gilead Sciences Inc · Expires 2022-11-24 · 3y expired

What this patent protects

Provided herein are compounds and methods for the treatment or prevention of Zika virus infection. For example, a compound of the formula(I). Wherein the variable substituents are described herein.

USPTO Abstract

Provided herein are compounds and methods for the treatment or prevention of Zika virus infection. For example, a compound of the formula(I). Wherein the variable substituents are described herein.

Drugs covered by this patent

Patent Metadata

Patent number: CA3219397A1
Jurisdiction: CA
Classification: —
Expires: 2022-11-24
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.